Cargando…

PMON66 A Systematic Literature Review to Evaluate Extended Dosing Intervals in the Pharmacological Management of Acromegaly

BACKGROUND: Acromegaly is a rare, lifelong disorder characterized by excess growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Extended dosing intervals (EDIs) of pharmacological treatments may reduce patient burden and costs compared with standard dosing. This systematic literature revie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fleseriu, Professor Maria, Hanman, Kate, Haria, Keval, Houchard, Aude, Khawaja, Sheila, Ribeiro-Oliveira Jr., Antonio, Zhang, Zhaoyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625355/ http://dx.doi.org/10.1210/jendso/bvac150.1163

Ejemplares similares

A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly
por: Fleseriu, M., et al.
Publicado: (2022)

PMON57 Impact of Injection Modalities on Real-World Injection Experience in Patients with Acromegaly or Neuroendocrine Tumors (NETs) Treated With Somatostatin Analog (SSA) Therapy: Data from the PRESTO 2 Survey
por: Ribeiro-Oliveira, Antonio, et al.
Publicado: (2022)

The Pharmacological Burden of Comorbidities in Acromegaly
por: Fleseriu, Maria, et al.
Publicado: (2021)

THU061 Treatment Patterns In Acromegaly: Analysis Of Real-World US Insurance Claims From The MarketScan(®) Database
por: Fleseriu, Maria, et al.
Publicado: (2023)

Use of Oral Concomitant Medications in Patients With Acromegaly
por: Petersenn, Stephan, et al.
Publicado: (2021)

PMON154 Cardiovascular Complications in Acromegaly-A National Inpatient Sample Analysis
por: Thota, Geethika, et al.
Publicado: (2022)

PMON101 Fluctuating Insulin Requirements in Untreated Acromegaly: From 200-to-0
por: Bellavia, Lauren, et al.
Publicado: (2022)

PMON161 Decreased serum Wnt antagonist levels in patients with active acromegaly
por: Chen, Huan, et al.
Publicado: (2022)

PMON166 Safety Comparison of 40- vs 60-mg/day Doses of Oral Octreotide Capsules for Treatment of Acromegaly in the CHIASMA OPTIMAL Trial
por: Elenkova, Atanaska, et al.
Publicado: (2022)

PMON61 Evaluation of elevated IGF-1 in patients without clinical evidence of acromegaly
por: Careless, Laura, et al.
Publicado: (2022)

PMON104 Sellar Gangliocytoma-Pituitary Neuroendocrine Tumor (PitNET) Presenting As Acromegaly
por: Aurora, John, et al.
Publicado: (2022)

RF13 | PMON159 Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly: MPOWERED Trial Open-Label Extension Phase
por: Fleseriu, Maria, et al.
Publicado: (2022)

PMON132 Biochemical and Radiologic Discordance in the Post-operative Surveillance of a Filipino Patient With Acromegaly
por: Enverga, Mariel C, et al.
Publicado: (2022)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

PMON75 Unilateral Galactorrhea in an Elderly Male
por: Monsour, Elio, et al.
Publicado: (2022)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

MON-308 Pituitary Magnetic Resonance Imaging in the Postoperative Follow-Up of Patients with Acromegaly, Less Is More!
por: Fernandes, Stuti, et al.
Publicado: (2020)

PMON163 Effect of Osilodrostat on Androgens and Adrenal Hormones in Patients With Cushing's Disease: Long-Term Findings From the Phase III, Prospective LINC 3 Study
por: Fleseriu, Maria, et al.
Publicado: (2022)

RF25 | PMON147 Plasma MicroRNA Expression in Phenocopy of Multiple Endocrine Neoplasia Type 1 Compared to Patients with Acromegaly and Primary Hyperparathyroidism: Potential Biomarkers of Multiple Endocrine Tumor Growth
por: Trukhina, Diana, et al.
Publicado: (2022)

PMON112 Primary Pituitary Lymphoma Presenting as Apoplexy
por: Abdelaziz, Sara, et al.
Publicado: (2022)

PMON117 IGF-1 Testing: Diagnostic Pitfalls
por: Perez-Martinez, Sebastian
Publicado: (2022)

PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat
por: Biller, Beverly M K, et al.
Publicado: (2022)

PMON88 A Rare Case of Composite Paraganglioma in the Bladder
por: Kreit, Helen, et al.
Publicado: (2022)

PMON89 Nephrogenic Diabetes Insipidus in a Patient on Temozolomide
por: Moll, Teresa, et al.
Publicado: (2022)

PMON155 Intraoperative, confocal laser endomicroscopy in pituitary surgery
por: Schlaffer, Sven-Martin, et al.
Publicado: (2022)

PMON70 Systemic Delivery of Leuprolide via Oral Administration
por: Shangold, Gary, et al.
Publicado: (2022)

PMON97 Pituitary Abscess: Long-term follow up
por: Hoang, Thanh, et al.
Publicado: (2022)

PMON100 IgG4 hypophysitis with granulomatous histopathology
por: Gultekin, Sakir, et al.
Publicado: (2022)

PMON90 Pituitary Abscess, A rare cause of Hypopituitarism
por: Cordeiro, Monica Fabiola Nogueira, et al.
Publicado: (2022)

PMON157 Evidence For Locally Produced Cortisol in Pituitary Tissue
por: Tsai, Karen, et al.
Publicado: (2022)

SAT-435 Optimization of Pharmacological Treatment of Acromegaly: Impact on IGF-1 Levels Comparing Isolated Octreotide LAR and Combined Pharmacological Therapy
por: Naves, Luciana, et al.
Publicado: (2019)

MON-306 Acromegaly Comorbidity Costs, Quality of Life, and Mortality: Lifetime Comparisons for Controlled Acromegaly, Uncontrolled Acromegaly, and the General US Population
por: Whittington, Melanie D, et al.
Publicado: (2020)

ODP320 Immune Organs Enlarged in Acromegaly: Evaluation of Thymus Volume in Patients with Acromegaly
por: Nahit Sendur, Suleyman, et al.
Publicado: (2022)

PMON99 A Rare Case of an Intrasellar Epidermoid Cyst And Panhypopituitarism
por: Azmath, Misbah, et al.
Publicado: (2022)

PMON130 Pituitary apoplexy presenting as left basal ganglia hemorrhage
por: Zahid, Maleeha, et al.
Publicado: (2022)

PMON129 Pituitary Adenoma Co-Secreting GH, Prolactin and ACTH
por: Wilson, Sarah, et al.
Publicado: (2022)

PMON149 Identification of TR4 Modulators for Treatment of Cushing Disease.
por: Zhang, Dongyun, et al.
Publicado: (2022)

PMON121 GALACTORRHEA, MACROPROLACTINOMA IN A 53-YEAR-OLD MALE
por: Selman-Geara, Antonio, et al.
Publicado: (2022)

PMON144 FOXO1 is required for glucocorticoid induced somatotrope maturation
por: Das, Pratyusa, et al.
Publicado: (2022)

PMON106 Persistent Prolactin Levels in a Patient with Pituitary Adenoma
por: Kadakia, Natasha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q7g09bmn0thaugoo2mf0nbbocl